Patients with newly diagnosed glioblastoma cancer are needed for a study to research an experimental cellular therapy.

IRB/UVA Tracking #
20105
Principal Investigator
Camilo Fadul
Contact
Jungeun Kim
Contact Email
Contact Phone
434.982.0074
Official Trial Title
A Phase I Study Targeting Newly Diagnosed Glioblastoma with anti-CD3 x anti-EGFR Bispecific Antibody Armed T cells (EGFR BATs) in Combination with Radiation and Temozolomide
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and are newly diagnosed with glioblastoma cancer. The purpose of this study to evaluate an experimental drug (EGFR-BATs) in patients with newly diagnosed glioblastoma cancer. The experimental drug dose, safety, and the effects of the drug will be evaluated for this study.

Participation is approximately 5 months. This includes a screening period, surgery, leukapheresis procedure, approximately 6 weeks of chemotherapy plus radiation therapy, 7 weeks of study drug treatment and possibly longer, with a longer term follow up via clinic visits. Study specific tests that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03344250

Compensation

This study does not offer compensation. Reimbursement: You may stay in hotel accommodations arranged by the study team if you live over 40 minutes away.